Post by
ChesterLives on Feb 22, 2024 3:39pm
Critical Care
Wasn't the premise of this report , with Kellum and 15 investigators participating, that The trial had a 96%+ probability of seccess, once it reached 90 patients.
In that context why are they carrying on.
Comment by
hmmmmmmmm on Feb 22, 2024 4:00pm
Because the FDA is the only one who coulld make such a determination, and the FDA was never going to look at it- the was fabricated completely by MM. The people that were going to look at it were Baxter- who now suddenly have no interest- saying they are paying their tiny ante - "blind". no validation, no confirmation.
Comment by
Spamme54321 on Feb 22, 2024 4:18pm
In the senacrio where Baxter had taken a look at the data then Spectral would have been required to release the same data to the public. Assuming the data is favourable. Then EDT's share price might have gone up even with the need of additional capital. If Vantive wanted to acquire Spectral as BlueJay believes then that outcome would be deterimental to them.
Comment by
ChesterLives on Feb 22, 2024 4:28pm
According to Critical Care, 15 investigators and Dr. Kellum say the data is extremely favourable... beyond favourable, BULLET PROOF. Bashers have a ton of ammo today. That is the company's fault! I expect every personality out in full force and they don't disappoint.
Comment by
BayStreetWild on Feb 23, 2024 8:03am
They've already acquired it. They have the distribution rights for 7M, why would they want the baggage that comes along with this team. They're not stupid?